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CASE REPORT
HYPERINFECTION BY Strongyloides stercoralis PROBABLY ASSOCIATED WITH RITUXIMAB IN A 
PATIENT WITH MANTLE CELL LYMPHOMA AND HYPER EOSINOPHILIA
Renzo Nino INCANI(1), Marcos HERNÁNDEZ(2) & María Elena GONZÁLEZ(3)
SUMMARY
The first report to our knowledge, of hyperinfection by Strongyloides stercoralis (HS) and hypereosinophilia, associated to immune 
suppression by Rituximab (the only drug received for the last one year and 10 months), in a patient with mantle-cell lymphoma 
(MCL), is presented. The patient has a 3-year history of MCL, and developed two accesses of HS during 2008, including meningitis, 
pneumonia and presence of larvae of S. stercoralis in the lungs. We had a unique chance to look at cytotoxicity of filariform larvae 
in the expectoration after Ivermectin treatment, showing immobilization and death of larvae, associated with eosinophils attached to 
the cuticle of the parasite. 
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INTRODUCTION
Hyperinfection by Strongyloides stercoralis (HS) is a well known 
clinical and parasitological event, in which the parasitic infection, usually 
limited to the intestinal wall of the upper small intestine, causing few 
or no symptoms, can spread to other areas of the gastro intestinal tract 
and to other organs; the latter is sometimes referred to as disseminated 
strongyloidiasis (DS)14,15,16. This situation is triggered by immune 
deficiency. Relevant causes of immune deficiencies associated with 
hyperinfection by S. stercoralis are malignancies such as lymphoma7,16, 
leukaemia14, immunosuppression with drugs, among which steroids 
are of major importance14,15,16, organ and tissue transplants5,19. In a high 
percentage of all these situations, treatment with immunosuppressive 
drugs, particularly steroids, seems to be important6. Steroids are known 
to suppress eosinophilia and lymphocyte activation4,14. Other important 
causes include coinfection with the human T cell lymphotropic virus type-
1 (HTLV-1)9,26, hypogammaglobulinemia and malnutrition14. Coinfection 
with HIV has also been implicated, although the views are somewhat 
conflicting and the accepted view is that there are no solid criteria to 
establish a relationship between HIV infection and HS14,16. The death 
rate from HS, particularly in the DS form, can be as high as 60-86% 7,13. 
Although Ivermectin at one or two doses per day is the drug of choice 
for S. stercoralis infection, the dosing for HS or DS does not appear to 
have been worked out yet, as it has not for Thiabendazole, an effective 
drug, but with side effects, or Albendazole, a much less effective drug14. 
In this paper we report a case of hyperinfection by S. stercoralis with 
hyper-eosinophilia and respiratory distress, in a patient with non-Hodgkin’s 
mantle cell lymphoma (MCL) receiving only Rituximab (anti-CD20 
monoclonal antibody) as maintenance treatment, not associated to HTLV-
1 infection, clinically cured with Ivermectin, and in which eosinophil 
cytotoxicity against larval stages in the lung could be documented. 
CASE DESCRIPTION
The patient was a 59-year-old Venezuelan-born female, with a 3-year 
history of MCL in clinical remission, after receiving Rituximab-Hyper-
CVAD, high dose Methotrexate and ARA-C for five cycles (October 
2005-April 2006), and maintenance with Rituximab alone for one year 
and 10 months before admission. She was admitted to hospital on the 6th 
of February 2008 with a diagnosis of meningitis caused by a coagulase-
negative Staphylococcus (apparently S. warneri), which was resolved 
with intravenous Vancomycin. However, fever and mild respiratory 
symptoms persisted. Three weeks later she was readmitted because 
of abdominal pain, diarrhea, persistent productive cough, fever and 
periodical symptoms of intestinal pseudo-obstruction. Fecal examination 
showed abundant larvae of S. stercoralis. Examination of expectoration 
samples revealed abundant filariform larvae of S. stercoralis (about 40 
larvae/50µL sputum). Klebsiella pneumoniae and Candida albicans were 
isolated from expectoration. Deterioration of health prompted admission 
to the Intensive Care Unit. Treatment included Cefotaxime 14 days, 
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Fluconazole seven days, and Ivermectin (200 µg/kg/day for two days), 
with improvement of the symptoms. New examination of the patient at 
day 7 after Ivermectin treatment showed diffuse abdominal pain and no 
visceromegalies, edema in both legs, dry, desquamate and itchy skin, fever 
and cough still persistent with white expectoration, the feces were solid. 
A second 2-day course of Ivermectin was repeated, with improvement 
of respiratory symptoms. Direct and agar culture of expectoration and 
fecal examination samples using the concentration method of Baermann, 
carried out at 30 and 52 days after 2nd Ivermectin treatment, did not 
show larvae of S. stercoralis. Four months after first admission (25 June 
2008), she again had pneumonia due to K. pneumoniae and was treated 
with Ceftazidine with clinical improvement, but high blood cell count 
(32,500/mm3) and eosinophilia (22,425/mm3) prompted examination of 
feces and expectoration, showing rabditiform larvae of S. stercoralis in 
both samples. She was previously medicated by others with Albendazole 
400 mg/day for five days with no success, and later by us with Ivermectin 
200 µg/kg/day for five days. Examination of feces (Direct, Baermann 
and agar plate23) and expectoration (Direct and agar plate) 12 days and 
two months after completion of treatment did not evidence the presence 
of larvae of S. stercoralis.
Background history: Lymphoma was diagnosed in April 2005 by 
biopsy of cervical lymph node. Chemotherapy-immunotherapy treatment 
Hyper-CVAD included three monthly cycles of Cyclophosphamide, 
Doxorubicin, Vincristine and dexamethasone, alternated with three 
monthly cycles of Methotrexate and Cytarabine, with Rituximab before 
each cycle22. Cycles of chemotherapy lasted until April 2006, after which 
only Rituximab bi-monthly was administered: in 2007 she received 
five doses, and in 2008 (up to August) four doses. She had frequent 
cough, diagnosed as bronchitis and findings of the chest tomography 
and x-ray were reported as interstitial bilateral infiltrates. Abdominal 
pain and diarrhea were reported since the beginning of chemotherapy 
for lymphoma, three years before admission. S. stercoralis infection 
was diagnosed in feces first time after last cycle of chemotherapy, and 
thereafter treated several times including a course of 1200 mg/day 
for three days with one day’s rest for four cycles, without complete 
success. Six months before admission, she was treated at our Clinic of 
Parasitology with a single 200 µg/kg dose of Ivermectin because of a 
diagnosis of strongyloidiasis infection. Gastrointestinal bleeding and 
hematuria associated to pancytopenia post chemotherapy was observed 
in February 2006. Upper endoscopy in March 2006 showed chronic 
gastritis and granular duodenitis. The patient has been a permanent city 
dweller for the last 34 years, with no rural contacts. The expected time 
of infection by S. stercoralis, according to prolonged rural contacts with 
limited sanitation, appears to be 49-58 and/or 34-43 years previously.
Laboratory
Relevant laboratory tests available since August 2007: Haemoglobin 
between 10 and 14 gr/dL, white blood cell counts between 9,000 and 
34,700/mm3, eosinophils between 1,344 and 22,425/mm3. Total proteins, 
albumin, globulins (range of normal values in mg/dL) around the time of 
first pneumonia: 5.3 (6.3-8.5), 3.4 (3.5-5.1), 1.9 (2.5-3.0) and two months 
after pneumonia: 5.7 (6.4-8.9), 4.4 (3.1-5.0), 0.1 (0.9-1.8) respectively. 
Immunoglobulins: IgG 212 (700-1600 mg/mL), IgM 16 (40-230 mg/
dL), IgE 7.5 (< 48 IU/mL) and IgA 46.3 (70-400 mg/dL). Cerebral-spinal 
fluid examination at the time of meningitis showed signs of bacterial 
infection, and the culture showed gram positive Staphylococcus. Cultures of 
expectoration at the time of first and second pneumonia infections showed 
Klebsiella pneumoniae and Candida albicans. Anti-core HBV was positive. 
S. stercoralis larvae in feces first time in April 2006, and thereafter several 
times diagnosed and incompletely treated until apparently successfully 
treated with Ivermectin (August 2007) six months before meningitis; 
again diagnosed at the time of first and second pneumonia infections. S. 
stercoralis larvae were observed in expectoration at time of first and second 
pneumonia infections. Culture of left external otitis secretion (May 2008) 
showed abundant growth of coagulase-negative Staphylococcus sp. HIV 
and HTLV I-II tests (carried out twice) were negative.
Cytotoxicity of Strongyloides stercoralis larvae: Expectoration 
samples provided a unique chance to look at filariform larval destruction. 
At day of diagnosis, larvae were all alive and moved vigorously. Two 
days after first 2-day doses of Ivermectin about 2/3 of the larvae were 
immobilized or with difficult movements, and surrounded by a cloud of 
cells (Fig. 1a). Most of the free cells and cells attached to the larval cuticle 
were eosinophils and some eosinophilic material could be detected at the 
parasite surface (Fig. 1b). By day 5 post Ivermectin, most larvae were 
dead or with little movements and surrounded by eosinophils.
Fig. 1 - In vivo eosinophil-mediated cytotoxicity against filariform larvae of Strongyloides 
stercoralis in the expectoration, taken at the first pneumonia episode, two days after Ivermectin 
treatment. a) Fresh sample of expectoration showing a live stunted larvae surrounded by a 
cloud of cells (x100). b) Wright staining of expectoration smear of the same material as a), 
showing almost exclusively eosinophils surrounding or attached to a live stunted larvae, and 
eosinophilic material (£) in the surface of the parasite (x400)
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White blood cell counts, Rituximab and Strongyloides stercoralis 
hyperinfection accesses: Figure 2 shows the total and differential white 
blood cells (WBC) counts that could be recovered from December 2007 
to July 2008. WBC counts were usually above normal throughout this 
period. Three peaks of eosinophilia were detected: the 1st coinciding with 
diagnosis of meningitis, the 2nd at the time of the first HS, and the 3rd 
coincided with a 2nd diagnosis of HS. Treatment of HS with Ivermectin 
and antibiotics resulted in clinical cure and a reduction in WBC counts. 
Lymphocyte counts were unremarkably constant throughout the period 
of observation. Rituximab applications did not appear to be associated 
to detectable changes in WBC counts.
DISCUSSION
Strongyloidiasis HS has a long lasting history of association with 
lymphoma, although it appears that it is more a consequence of the 
immunosuppressive treatment of this malignancy, particularly the use 
of steroids. The first diagnosis of strongyloidiasis in our patient was 
made after the last cycle of chemotherapy-immunotherapy of mantle 
cell lymphoma. Thereafter, she was diagnosed of strongyloidiasis several 
times before admission and treated with Albendazole, without eradication 
of the parasite. The cycles of chemotherapy-immunotherapy with 
Rituximab-Hyper-CVAD included the corticosteroid dexamethasone, 
known to be associated with HS, and could explain the first exacerbations 
of the parasite infection. However, the actual relapses of HS do not appear 
to be related to steroid treatment since the cycles of chemotherapy-
immunotherapy were concluded one year and 10 months before 
admission. Since the only immunosuppressive drug she has been 
receiving thereafter (and is still receiving) is Rituximab, a relationship 
between HS and this drug could be postulated.
Rituximab is a chimeric murine/human monoclonal antibody 
anti-CD20, an antigen present in B lymphocytes and in most B cells 
of non-Hodgkin’s lymphoma. In vitro evidence shows that Rituximab 
works with the human immune system to induce B-cell lysis through an 
antibody-dependent cell-mediated cytotoxicity, complement-dependent 
cytotoxicity and stimulates apoptosis2. It can also induce neutropenia18. 
There are reports in which Rituximab alone or its addition to standard 
chemotherapy schedules for lymphoma has increased the risk of life-
threatening infections, either opportunistic or not, such as bacterial, fungal, 
protozoan, viral and viral reactivations3. However, it appears that infections 
are more frequent in HIV-associated B-cell lymphoma. To our knowledge, 
ours appears to be the first report of a helminth opportunistic infection that 
could be related to a B-cell immunosuppressant agent. Rituximab also 
induces a reduction in immunoglobulin levels particularly IgG12 and IgM8. 
It has been shown that B-cells and IgM are relevant in immunity against S. 
stercoralis, and probably prevent the parasite spreading1,10.
Eosinopenia, or at least absence of eosinophilia, is associated with 
most conditions in which immunodeficiency leads to S. stercoralis 
hyperinfection and consequently to high lethality6,13. On the other 
hand, patients with strongyloidiasis and hyper eosinophilia appear 
to survive longer6,20 and may have few symptoms in spite of immune 
suppression25. Our case is unusual in the fact that hyper-eosinophilia has 
been constant throughout eight months of observation. Eosinophilia has 
been considered a good prognosis factor in cases of HS 14,25, a contention 
which is reinforced by the survival of this patient to meningitis and 
pneumonia, both highly lethal complications in HS. This may lead to 
think that hyper-eosinophilia and larval destruction by an antibody-
dependent eosinophil-mediated cytotoxicity, after Ivermectin initial 
damage to the parasite, may have been a major cause for survival and 
quick health recovery of this patient. This in spite of low serum levels 
of total immunoglobulins subclasses detected in this patient. However, 
some specific IgE response against parasite antigens could be detected 
in her serum (not shown in this paper). 
Eosinophils are major effector cells of cytotoxicity against larval 
stages of parasitic helminths11. If eosinophils are not available in sufficient 
quantities, cytotoxicity may not be efficient, once treatment has been 
administered. It appears that in this immunosuppressed patient, there 
may be a potentiation between the drug and the eosinophil damage to 
the parasite, as it has been observed experimentally in filarial infections 
with Ivermectin21 or Diethylcarbamazine17. 
Failure of Ivermectin treatment is another point to consider. The 
patient had been unsuccessfully treated with frequent and prolonged 
doses of Albendazole. Eventually, as Ivermectin became available to this 
patient, she received several schemes with therapeutic failures, until a 
continuous five dose per day scheme was administered, with successful 
disappearance of larvae in feces and sputum. The only condition we have 
found in the literature related to drug failure in strongyloidiasis treated 
with Albendazole, Thiabendazole or Ivermectin, is coinfection with 
the HTLV-1 virus26. Our patient does not appear to be coinfected with 
HTLV-1 and other explanations like immune suppression by Rituximab 
or insufficient Ivermectin doses should be sought.
RESUMEN
Hiperinfección por Strongyloides stercoralis probablemente 
asociada con Rituximab en una paciente con linfoma e 
hipereosinofilia
Se presenta el primer reporte, hasta donde tengamos información, 
de hiperinfección por Strongyloides stercoralis (HS) e hipereosinofilia 
asociados a inmunosupresión por Rituximab (el único medicamento 
recibido durante 1 año y 10 meses), en un paciente con linfoma de células 
Fig. 2 - Total and differential white blood cell counts that could be collected from the patient 
between 26th December 2007 and 7th August 2008 and the following events: (ñ) Rituximab 
applications, (Ø) meningitis and (á) episodes of hyperinfection of Strongyloides stercoralis 
detected in the intestine and lungs. (£) Total number of white blood cells, () Neutrophils, 
(p) eosinophils, (¯) lymphocytes
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del manto (LCM). La paciente tuvo una historia de 3 años con LCM, 
y desarrolló 2 accesos de HS durante el 2008, incluyendo meningitis, 
neumonía y presencia de larvas de S. stercoralis en los pulmones. Se 
tuvo la oportunidad única de observar la citotoxicidad contra las larvas 
filariformes en la expectoración, luego del tratamiento con Ivermectina, 
mostrando la inmovilización y muerte de las larvas, asociada a la 
presencia de eosinófilos adheridos a la cutícula del parásito.
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